• Mashup Score: 0
    Study Shows Heart Failure Treatment With Dapagliflozin Consistently Benefited Both Men and Women - 2 year(s) ago

    November 14, 2022 — When it comes to heart failure (HF), sex differencesare known to impact everything from risk factors to clinical presentation to response to treatment, making sex a key factor to consider in studies of emerging pharmacotherapies. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, such as dapagliflozin, have become an important pharmacotherapy solution for patients with HF, yet…

    Source: DAIC
    Categories: Cardiologists, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of DAICeditor
      DAICeditor

      @DAICeditor @BWHCVImaging Investigators from Brigham and Women's Hospital conducted a study using a pre-specified patient-level pooled analysis of #DAPA_HF and #DELIVER: https://t.co/yJ6fyy5hVj #dapagliflozin #heartfailure

  • Mashup Score: 2
    Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Preserved Ejection Fraction - 2 year(s) ago

    This prespecified analysis of the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) randomized clinical trial investigates if the effects of dapagliflozin on cardiovascular events vary with baseline kidney function.

    Source: jamanetwork.com
    Categories: Cardiologists, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of GiuseppeGalati_
      GiuseppeGalati_

      #DELIVER 🔥 #Dapa efficacy in #HFmrEF & #HFpEF across the full spectrum of renal function 🧩 Another piece of the puzzlereinforcing the recent metanalysis on #SGLT2i on kidney function @mvaduganathan @BrighamResearch @gcfmd @KardiologieHH @DrMarthaGulati https://t.co/UvhNzEFbP1 https://t.co/hOoiIWQRWt

  • Mashup Score: 3
    Home | delivertrial - 2 year(s) ago

    DELIVER was a randomized, placebo-controlled, double-blind international clinical outcomes trial testing the hypothesis that dapagliflozin compared with placebo would reduce the risk of cardiovascular death or worsening heart failure in patients with heart failure with mildly reduced or preserved ejection fraction.

    Source: delivertrial
    Categories: Cardiologists, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of mvaduganathan
      mvaduganathan

      RT @scottdsolomon: Ankeet Bhatt presented the #DELIVER Covid-19 data today at AHA. View presentation at https://t.co/Z5qR42jsDu https://t.c…

  • Mashup Score: 0
    Home | delivertrial - 2 year(s) ago

    DELIVER was a randomized, placebo-controlled, double-blind international clinical outcomes trial testing the hypothesis that dapagliflozin compared with placebo would reduce the risk of cardiovascular death or worsening heart failure in patients with heart failure with mildly reduced or preserved ejection fraction.

    Source: delivertrial
    Categories: Cardiologists, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of mvaduganathan
      mvaduganathan

      New #DELIVER trial website just launched summarizing publications to date. A glimpse at 3 #AHA22 simpub & 2 related articles containing #DELIVER data to be pub at this meeting. Impressively, website entirely homegrown by sole designer: @scottdsolomon https://t.co/4rSHsGb6pQ https://t.co/NpXoeWEfwR https://t.co/anNXFj7FLg

  • Mashup Score: 9
    Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Preserved Ejection Fraction - 2 year(s) ago

    This prespecified analysis of the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) randomized clinical trial investigates if the effects of dapagliflozin on cardiovascular events vary with baseline kidney function.

    Source: jamanetwork.com
    Categories: Cardiologists, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of HanCardiomd
      HanCardiomd

      #Dapagliflozin and Kidney Outcomes in Patients With #HeartFailure With Mildly Reduced or Preserved Ejection Fraction : A Prespecified Analysis of the #DELIVER Trial #HeartFailure #HFpEF #HFmrEF https://t.co/YP24gmTeMM @JavedButler1 @scottdsolomon @DrMarthaGulati @kidney_boy https://t.co/ZYcFXbbSNa https://t.co/ohhmVI51tx

  • Mashup Score: 12
    Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Preserved Ejection Fraction - 2 year(s) ago

    This prespecified analysis of the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) randomized clinical trial investigates if the effects of dapagliflozin on cardiovascular events vary with baseline kidney function.

    Source: jamanetwork.com
    Categories: Cardiologists, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of mvaduganathan
      mvaduganathan

      #DELIVER Kidney now #SimPub w @ASNKidney/#KidneyWk LBCT in @JAMACardio ⭐️Consistent dapa safety & benefit on HF outcomes across eGFR range (down to 20) ⭐️Dapa predictable early eGFR dip & slowed long-term eGFR decline ⭐️Very few kidney composite outcomes https://t.co/LVLQYlP9vC https://t.co/4nL2Vwu8dN

  • Mashup Score: 2
    In HF, dapagliflozin benefits similar in patients with improved vs. consistently high EF - 2 year(s) ago

    NATIONAL HARBOR, Md. — In a DELIVER subgroup analysis, dapagliflozin conferred similar benefit in patients with HF with improved ejection fraction prior to trial enrollment compared with those with consistently high EF.“Heart failure with improved ejection fraction … has been recently defined as heart failure with previously reduced left ventricular ejection fraction of 40% or less,

    Source: www.healio.com
    Categories: Cardiology News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CardiologyToday
      CardiologyToday

      In a #DELIVER subgroup analysis, #dapagliflozin conferred similar benefit in patients with HF with improved EF prior to trial enrollment compared with those with consistently high EF @orlyvardeny @UMNews @HFSA #HFSA2022 #Cardiotwitter https://t.co/KMOirNP85U

Load More